ACP
RAPP

Acuta Capital Partners’s Rapport Therapeutics RAPP Stock Holding History

Acuta Capital Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$227K – 35
2025
Q2 		$227K Buy
20,000
+3,600
+22% +$38.2K 0.32% 26
2025
Q1 		$164K Hold
16,400
– – 0.19% 30
2024
Q4 		$291K Sell
16,400
-1,200
-7% -$26.6K 0.29% 38
2024
Q3 		$360K Sell
17,600
-2,400
-12% -$51.6K 0.29% 35
2024
Q2 		$465K Buy
+20,000
New +$463K 0.39% 28

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acuta Capital Partners's RAPP Position: Q3 2025 in Review

Acuta Capital Partners sold out of Rapport Therapeutics (RAPP) in Q3 2025, closing a stake of 20,000 shares — an estimated $227K sold.

Acuta Capital Partners first reported a position in RAPP in Q2 2024 and held it in 5 quarters. The position peaked at $465K in Q2 2024. 124 funds tracked by Wall St. Rank hold RAPP as of Q3 2025.

  • Acuta Capital Partners reported no remaining Rapport Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 20,000 Rapport Therapeutics shares in Q3 2025, an estimated $227K.
  • Acuta Capital Partners first reported a position in Rapport Therapeutics in Q2 2024 and held it in 5 quarters.
  • Acuta Capital Partners's Rapport Therapeutics position peaked at $465K in Q2 2024.
  • 124 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2025.

Based on Acuta Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.